Phase 2 N=9 Medical Treatment of "High-Risk" Neurofibromas
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=89 Neurobiology and Treatment of Reading Disability in NF-1
Neurofibromatosis Type 1 · Reading Disabilities
Primary: Change From Baseline in WJ-III Basic Reading Normative Update (Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III NU) Standard Score at 15 Hours — 13.50…
Phase 2 N=11 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Phase 2 N=62 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
Phase 2 N=21 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Neurofibromatosis 2 · Vestibular Schwannoma
Primary: Estimated Volumetric Progression Free Survival at 12 Months — 70.6 Liklihood of PFS at 12 months
Early Phase 1 N=6 Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants
N/A N=55 Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Phase 2 N=36 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Neurofibromatosis
Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume
Phase 2 N=86 Study of PEG-Intron for Plexiform Neurofibromas
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
Phase 2 N=10 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Phase 2 N=23 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Neurofibromatosis Type 1 · Precancerous Condition
Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Phase 2 N=45 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Phase 2 N=48 NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Neurofibromatosis 1 · Cutaneous Neurofibroma
Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…
Phase 2 N=45 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Phase 2 N=24 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Phase 2 N=199 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Cutaneous Neurofibroma · Neurofibromatosis 1
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants
Phase 2 N=13 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis Type 2 · Vestibular Schwannomas
Primary: Expression Levels of p-S6 Based Immunohistochemistry (Histoscore) — 90 score
N/A N=20 HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy
Cutaneous Neurofibroma
Primary: Short Term Safety Profile - Adverse Events — 0; 20 Participants
Phase 2 N=14 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Phase 2 N=9 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
Phase 2 N=19 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
Phase 2 N=62 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
N/A N=12 Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Proportion of Enrolled Participants for Which we Are Able to Collect Data From the Medication Event Monitoring Systems (MEMS^TM) System for Two or More Cycles of…
Phase 2 N=21 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Phase 2 N=5 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
Phase 2 N=146 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Neurofibromatosis Type 1
Primary: Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery). — 15.8; 17.0; 10.3; 11.7 PAL Total Errors — p=0.51
Phase 2 N=21 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Phase 1 N=1 Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Neurofibromatoses
Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001
Phase 2 N=25 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…